{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"4.9","upperLimit":"22.1","value":"11.6"},{"groupId":"OG001","lowerLimit":"5.6","upperLimit":"14.5","value":"11.7"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"31"},{"groupId":"OG001","value":"32"}],"units":"Participants"}],"description":"Measured from date of first treatment until date of first documented progression as per International Myeloma Working Group Uniform Response Criteria. Progressive disease id defined as an increase of ≥ 25% from the nadir in at least one of the following criteria: serum M-protein (absolute increase must be ≥0.5 g/dL); urine M-protein (absolute increase must be ≥200 mg/24h) ; only in patients with non-measurable serum and urine M-protein levels: difference in involved and uninvolved FLC levels (absolute increase must be \\>10 mg/dL); only in patients with non-measurable serum and urine M-protein levels and non-measurable disease by FLC levels, bone marrow plasma cell percentage (absolute % must be ≥10%) OR Definite development of new bone lesions or soft tissue plasmacytomas OR definite increase in the size of existing bone lesions or soft tissue plasmacytomas OR Development of hypercalcemia (corrected serum Ca \\>11.5mg/dL) for patients without hypercalcemia at baseline","dispersionType":"95% Confidence Interval","groups":[{"description":"Carfilzomib : cycle 1 - 20 mg/m\\^2 IV D1, 2 ; 45 mg/m\\^2 IV D 8, 9, 15, 16 cycle 2 to progression - 45 mg/m\\^2 IV D 1, 2, 8, 9, 15, 16\n\nPanobinostat : cycle 1 and cycle 2 to progression - 30 mg D 1, 3, 5, 15, 17, 19","id":"OG000","title":"Dose Level 4 - Escalation and Expansion"},{"description":"Carfilzomib : cycle 1 - 20 mg/m\\^2 IV D1, 2 ; 56 mg/m\\^2 IV D 8, 9, 15, 16 cycle 2 to progression - 56 mg/m\\^2 IV D 1, 2, 8, 9, 15, 16\n\nPanobinostat : cycle 1 and cycle 2 to progression - 20 mg D 1, 3, 5, 15, 17, 19","id":"OG001","title":"Dose Level 6 - Escalation and Expansion"}],"paramType":"MEDIAN","populationDescription":"All patients receiving dose level 4 and dose level 6 doses (both escalation and expansion phases combined) who had a post-baseline disease assessment per protocol were included in the analysis. 3 patients in dose level 4 and 1 patient in dose level 6 did not have a post-baseline assessment and were excluded from analysis.","reportingStatus":"POSTED","timeFrame":"up to 6 years","title":"Time-to-progression (TTP)","type":"SECONDARY","unitOfMeasure":"months"}